Monday, February 16, 2026
28 C
Bengaluru

Is Your Field Force Optimised to Make the Most of Market Growth in Metros?

Summary of Performance of Top 30 Metros in IPM – Dec’24

Overall Market Performance
• The top 30 metros in India contributed 34% to the total IPM (Indian Pharmaceutical Market) sales for MAT (Moving Annual Total) Dec’24.
• These cities grew at a rate of 8.5%, slightly higher than the overall IPM growth of 7.6%.
• The total market value of these 30 metros increased from ₹71,831 Cr (Dec’23) to ₹77,929 Cr (Dec’24), showing a ₹6,098 Cr increase.

Fastest-Growing Markets
• Top 5 fastest-growing metros:
1. Pune (15%)
2. Agra (14%)
3. Lucknow (13%)
4. Nashik (13%)
5. Delhi (12.5%)
Among the six mega metros, Delhi grew the fastest at 12.5%, followed by Chennai (11.6%) and Hyderabad (10.5%).

Growth Trends & Insights
• 13 out of 30 metros grew faster than the IPM growth rate (7.6%), while 17 metros grew at or below the IPM growth rate.
• Cities like Delhi, Hyderabad, Bangalore, and Chennai remain dominant in total market value, with Delhi leading at ₹10,756 Cr.
• Smaller cities like Bhopal (12%) and Nashik (13%) showed strong growth, indicating increasing pharmaceutical demand in Tier-2 cities.

Conclusion

The Indian pharmaceutical market continues to grow robustly, especially in urban centers. While mega metros remain strong contributors, smaller cities like Lucknow, Pune, and Agra are emerging as high-growth markets. The steady expansion of IPM in these metros suggests increasing healthcare accessibility and demand for pharmaceutical products in urban India.

Hot this week

Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich

When a new cancer drug shows promise, it trends...

From Overuse to Overreaction: Recalibrating India’s C-Section Debate

India’s caesarean section debate is drifting toward polarisation. On one...

Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift

In big pharma, leadership changes are rarely impulsive. They...

THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL

How a niche Indian topicals manufacturer outgrew its CDMO...

Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?

Transparency, Trust, and the Problem of “Invisible Evidence” in...

Topics

From Overuse to Overreaction: Recalibrating India’s C-Section Debate

India’s caesarean section debate is drifting toward polarisation. On one...

Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift

In big pharma, leadership changes are rarely impulsive. They...

THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL

How a niche Indian topicals manufacturer outgrew its CDMO...

Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?

Transparency, Trust, and the Problem of “Invisible Evidence” in...

The Uncomfortable Truth about Indian Generics: Untangling the Conundrum

India’s pharmaceutical industry occupies a unique and powerful position...

IQVIA vs. PharmaTrac: Indian Pharma Market Data

Here is an analytical blog comparing the IQVIA MFR...
spot_img

Related Articles

spot_imgspot_img